Skip to main content

Table 2 G6PD deficiency status amongst males and females participants per primary health care clinic according to the CareStart™ G6PD RDT

From: Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa

CareStartâ„¢ G6PDd RDT classificationa

Males (n, %)

Females (n, %)

Deficient (10, 18%)

Normal (45, 82%)

Deficient (23, 12%)b

Normal (170, 88%)c

Primary health care clinicsa

Folovhodwe

2 (4%)

8 (14%)

7 (4%)

36 (19%)

Madimbo

1 (2%)

5 (9%)

1 (0.5%)

50 (26%)

Manenzhe

1 (2%)

8 (14%)

5 (3%)

33 (17%)

Masisi

2 (4%)

9 (16%)

3 (1%)

22 (11%)

Mulala

2 (4%)

5 (9%)

5 (3%)

6 (3%)

Tshipise

2 (4%)

10 (18%)

2 (1%)

23 (12%)

  1. aNo of participants and (%) indicated
  2. bFrom the deficient females by CareStartâ„¢ G6PD RDT test, 2 were homozygous, 7 heterozygous and 14 normal
  3. cFrom the 170 normal females, 25 were heterozygous and 145 normal